Analyst: Powell Adopts a "Two-Faced" Strategy, Talking Hawkish to Appease the Rate Hikers, While Dragging His Feet in Action
BlockBeats News, July 2nd, institutional analyst Andrew Sacher stated that after Fed Chair Powell made his debut at the June FOMC meeting, the market is still debating his stance—is he a hawk or a dove? Due to internal FOMC disagreements on whether the next step is to raise interest rates or keep them unchanged, Powell's position is particularly important. The Sintra conference will provide a new opportunity to reassess his stance.
Sacher believes that Powell is first and foremost a politician, and his remarks at the FOMC meeting are balanced for both sides—we expect a similar strategy to be taken at Sintra. As he focuses on price stability, his comments may lean hawkish, aiming to appease a significant portion of the committee who want the Fed to demonstrate its independence from Trump by raising interest rates.
Powell's actions so far—such as setting up five working groups to review key Fed issues—have bought time for the next steps.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bayan Resources and its subsidiaries declare force majeure on coal supply agreements
MoffettNathanson raises SpaceX target price to $142
Survival Nearly Doubles! BioNTech (BNTX.US) Lung Cancer Candidate Drug PRESERVE-003 Achieves Success in Late-Stage Trial, Providing Critical Support for Oncology Transformation
BioNTech (BNTX.US) announced on Monday that a late-stage clinical trial demonstrated its candidate drug gotistobart provided a clinically meaningful overall survival benefit compared to standard therapy in a specific type of lung cancer.

